Introduction
In superovulated women, the endogenous luteinizing hormone (LH) surge is markedly attenuated (Messinis et al, 1985) . The attenuation has been related to a putative nonsteroidal ovarian factor called gonadotrophin surge-attenuating factor (GnSAF) (Messinis and Templeton, 1989) . The effect of GnSAF is exerted at least at the pituitary level where it reduces luteinizing-hormonereleasing hormone (LHRH)-stimulated gonadotrophin secretion (Messinis and Templeton, 1990a) . Activity of GnSAF has been detected during the follicular phase of superovulated cycles (Messinis and Templeton, 1990b) . In that respect, the role of GnSAF is not limited to the time of the midcycle LH surge, but is also extended at least to the first half of the cycle when it controls LHRH-induced gonadotrophin release by a negative effect (Messinis and Templeton, 1991a) . Several studies using various in vitro bioassay systems have shown activity of GnSAF, distinct from inhibin, in steroid-free human follicular fluid from superovulated and spontaneous cycles (Busbridge et al, 1990; Fowler et al, 1990a; Knight et al, 1990) .
During the luteal phase of superovulated cycles basal gonado¬ trophin secretion is markedly reduced (Messinis and Templeton, 1987) . In one study, the midluteal pituitary response to a phar¬ macological dose of LHRH was also decreased (Martikainen et al, 1987) . However, it is unclear whether GnSAF is produced (Wang et al, 1976; Yen and Lein, 1976) . In superovulated cycles, the two pools of gonadotrophin secretion are markedly attenuated by GnSAF and this can be used as an in vivo bioassay to assess the activity of GnSAF in superovulated women (Messinis and Templeton, 1991b; Messinis et al, 1991) .
In the present study a similar approach was used to investigate GnSAF bioactivity during the luteal phase of FSH superovulated cycles. (Fig. 1) .
Materials and Methods

Patients
In the late follicular phase (Fig. 2 (Fig. 2) (28.4 +3.2and2.9 + 0.4 iul" \ respectively) to mid-(21.0 ± 2.2 and 2.0 + 0.2 iu l"1, respectively, < 0.05) and late luteal phase of the spontaneous cycles (16.0 + 1.5 iu 1~ , < 0.01 and 1.4 +0.1iul_I,P< 0.05, respectively) (Fig. 3) . The decrease from mid-to late luteal phase was also significant for both LH30 and AFSH30 (P < 0.05). In the FSH cycles, ALH30 and AFSH30 were significantly attenuated compared with the spontaneous cycles in early (6.2 + 1.1 and 0.5 + 0.1 iul-1, respectively, P< 0.001),mid-(6.3 + 1.3iul_I,P< 0.01and0.5 ± 0.1 iul"1, < 0.001, respectively) and late luteal (6.0 + 0.7 iul"1, (Farnworth et al, 1988; Knight et al, 1991) . In addition, higher concentrations of inhibin are required for the suppression of LHRH-stimulated than for basal FSH release in rat pituitary cultures (Farnworth et al, 1988) . The extent to which these data apply to humans is not known. Nevertheless, in the present study, basal concentrations of FSH in the FSH cycles increased in all women from mid-to late luteal phase (Fig. 1) (Busbridge et al, 1990; Fowler et al, 1990a; Knight et al, 1990) and has a molecular mass in the range of 10-30 kDa (Fowler et al, 1992 
